1
|
McKaige EA, Lee C, Calcinotto V, Giri S, Crawford S, McGrath MJ, Ramm G, Bryson-Richardson RJ. Mitochondrial abnormalities contribute to muscle weakness in a Dnajb6 deficient zebrafish model. Hum Mol Genet 2024; 33:1195-1206. [PMID: 38621658 PMCID: PMC11227618 DOI: 10.1093/hmg/ddae061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Revised: 02/28/2024] [Accepted: 03/28/2024] [Indexed: 04/17/2024] Open
Abstract
Mutations in DNAJB6 are a well-established cause of limb girdle muscular dystrophy type D1 (LGMD D1). Patients with LGMD D1 develop progressive muscle weakness with histology showing fibre damage, autophagic vacuoles, and aggregates. Whilst there are many reports of LGMD D1 patients, the role of DNAJB6 in the muscle is still unclear. In this study, we developed a loss of function zebrafish model in order to investigate the role of Dnajb6. Using a double dnajb6a and dnajb6b mutant model, we show that loss of Dnajb6 leads to a late onset muscle weakness. Interestingly, we find that adult fish lacking Dnajb6 do not have autophagy or myofibril defects, however, they do show mitochondrial changes and damage. This study demonstrates that loss of Dnajb6 causes mitochondrial defects and suggests that this contributes to muscle weakness in LGMD D1. These findings expand our knowledge of the role of Dnajb6 in the muscle and provides a model to screen novel therapies for LGMD D1.
Collapse
Affiliation(s)
- Emily A McKaige
- School of Biological Sciences Monash University, 25 Rainforest Walk, Clayton, VIC 3800, Australia
| | - Clara Lee
- School of Biological Sciences Monash University, 25 Rainforest Walk, Clayton, VIC 3800, Australia
| | - Vanessa Calcinotto
- School of Biological Sciences Monash University, 25 Rainforest Walk, Clayton, VIC 3800, Australia
| | - Saveen Giri
- Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, 23 Innovation Walk, Clayton, VIC 3800, Australia
| | - Simon Crawford
- Monash Ramaciotti Centre for Cryo Electron Microscopy, Monash University, 15 Innovation Walk, Clayton, VIC 3800, Australia
| | - Meagan J McGrath
- Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, 23 Innovation Walk, Clayton, VIC 3800, Australia
| | - Georg Ramm
- Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, 23 Innovation Walk, Clayton, VIC 3800, Australia
- Monash Ramaciotti Centre for Cryo Electron Microscopy, Monash University, 15 Innovation Walk, Clayton, VIC 3800, Australia
| | | |
Collapse
|
2
|
Findlay AR, Paing MM, Daw JA, Haller M, Bengoechea R, Pittman SK, Li S, Wang F, Miller TM, True HL, Chou TF, Weihl CC. DNAJB6 isoform specific knockdown: Therapeutic potential for limb girdle muscular dystrophy D1. MOLECULAR THERAPY. NUCLEIC ACIDS 2023; 32:937-948. [PMID: 37346979 PMCID: PMC10280091 DOI: 10.1016/j.omtn.2023.05.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/17/2022] [Accepted: 05/10/2023] [Indexed: 06/23/2023]
Abstract
Dominant missense mutations in DNAJB6, a co-chaperone of HSP70, cause limb girdle muscular dystrophy (LGMD) D1. No treatments are currently available. Two isoforms exist, DNAJB6a and DNAJB6b, each with distinct localizations in muscle. Mutations reside in both isoforms, yet evidence suggests that DNAJB6b is primarily responsible for disease pathogenesis. Knockdown treatment strategies involving both isoforms carry risk, as DNAJB6 knockout is embryonic lethal. We therefore developed an isoform-specific knockdown approach using morpholinos. Selective reduction of each isoform was achieved in vitro in primary mouse myotubes and human LGMDD1 myoblasts, as well as in vivo in mouse skeletal muscle. To assess isoform specific knockdown in LGMDD1, we created primary myotube cultures from a knockin LGMDD1 mouse model. Using mass spectrometry, we identified an LGMDD1 protein signature related to protein homeostasis and myofibril structure. Selective reduction of DNAJB6b levels in LGMDD1 myotubes corrected much of the proteomic disease signature toward wild type levels. Additional in vivo functional data is required to determine if selective reduction of DNAJB6b is a viable therapeutic target for LGMDD1.
Collapse
Affiliation(s)
- Andrew R. Findlay
- Department of Neurology, Neuromuscular Division, Washington University School of Medicine, Saint Louis, MO 63110, USA
| | - May M. Paing
- Department of Neurology, Neuromuscular Division, Washington University School of Medicine, Saint Louis, MO 63110, USA
| | - Jil A. Daw
- Department of Neurology, Neuromuscular Division, Washington University School of Medicine, Saint Louis, MO 63110, USA
| | - Meade Haller
- Department of Neurology, Neuromuscular Division, Washington University School of Medicine, Saint Louis, MO 63110, USA
| | - Rocio Bengoechea
- Department of Neurology, Neuromuscular Division, Washington University School of Medicine, Saint Louis, MO 63110, USA
| | - Sara K. Pittman
- Department of Neurology, Neuromuscular Division, Washington University School of Medicine, Saint Louis, MO 63110, USA
| | - Shan Li
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA
| | - Feng Wang
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA
| | - Timothy M. Miller
- Department of Neurology, Neuromuscular Division, Washington University School of Medicine, Saint Louis, MO 63110, USA
| | - Heather L. True
- Department of Cell Biology and Physiology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8228, St. Louis, MO 63110, USA
| | - Tsui-Fen Chou
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA
| | - Conrad C. Weihl
- Department of Neurology, Neuromuscular Division, Washington University School of Medicine, Saint Louis, MO 63110, USA
| |
Collapse
|
3
|
Administration of a single dose of lithium ameliorates rhabdomyolysis-associated acute kidney injury in rats. PLoS One 2023; 18:e0281679. [PMID: 36795689 PMCID: PMC9934413 DOI: 10.1371/journal.pone.0281679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Accepted: 01/27/2023] [Indexed: 02/17/2023] Open
Abstract
Rhabdomyolysis is characterized by muscle damage and leads to acute kidney injury (AKI). Clinical and experimental studies suggest that glycogen synthase kinase 3β (GSK3β) inhibition protects against AKI basically through its critical role in tubular epithelial cell apoptosis, inflammation and fibrosis. Treatment with a single dose of lithium, an inhibitor of GSK3β, accelerated recovery of renal function in cisplatin and ischemic/reperfusion-induced AKI models. We aimed to evaluate the efficacy of a single dose of lithium in the treatment of rhabdomyolysis-induced AKI. Male Wistar rats were allocated to four groups: Sham, received saline 0.9% intraperitoneally (IP); lithium (Li), received a single IP injection of lithium chloride (LiCl) 80 mg/kg body weight (BW); glycerol (Gly), received a single dose of glycerol 50% 5 mL/kg BW intramuscular (IM); glycerol plus lithium (Gly+Li), received a single dose of glycerol 50% IM plus LiCl IP injected 2 hours after glycerol administration. After 24 hours, we performed inulin clearance experiments and collected blood / kidney / muscle samples. Gly rats exhibited renal function impairment accompanied by kidney injury, inflammation and alterations in signaling pathways for apoptosis and redox state balance. Gly+Li rats showed a remarkable improvement in renal function as well as kidney injury score, diminished CPK levels and an overstated decrease of renal and muscle GSK3β protein expression. Furthermore, administration of lithium lowered the amount of macrophage infiltrate, reduced NFκB and caspase renal protein expression and increased the antioxidant component MnSOD. Lithium treatment attenuated renal dysfunction in rhabdomyolysis-associated AKI by improving inulin clearance and reducing CPK levels, inflammation, apoptosis and oxidative stress. These therapeutic effects were due to the inhibition of GSK3β and possibly associated with a decrease in muscle injury.
Collapse
|
4
|
Findlay AR, Robinson SE, Poelker S, Seiffert M, Bengoechea R, Weihl CC. LGMDD1 natural history and phenotypic spectrum: Implications for clinical trials. Ann Clin Transl Neurol 2022; 10:181-194. [PMID: 36427278 PMCID: PMC9930420 DOI: 10.1002/acn3.51709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Accepted: 11/15/2022] [Indexed: 11/26/2022] Open
Abstract
OBJECTIVE To delineate the full phenotypic spectrum and characterize the natural history of limb girdle muscular dystrophy type D1 (LGMDD1). METHODS We extracted age at clinical events of interest contributing to LGMDD1 disease burden via a systematic literature and chart review. Manual muscle testing and quantitative dynamometry data were used to estimate annualized rates of change. We also conducted a cross-sectional observational study using previously validated patient-reported outcome assessments (ACTIVLIM, PROMIS-57) and a new LGMDD1 questionnaire. Some individuals underwent repeat ACTIVLIM and LGMDD1 questionnaire assessments at 1.5 and 2.5 years. RESULTS A total of 122 LGMDD1 patients were included from 14 different countries. We identified two new variants (p.E54K, p.V99A). In vitro assays and segregation support their pathogenicity. The mean onset age was 29.7 years. Genotype appears to impact onset age, weakness pattern, and median time to loss of ambulation (34 years). Dysphagia was the most frequent abnormality (51.4%). Deltoids, biceps, grip, iliopsoas, and hamstrings strength decreased by (0.5-1 lb/year). Cross-sectional ACTIVLIM and LGMDD1 questionnaire scores correlated with years from disease onset. Longitudinally, only the LGMDD1 questionnaire detected significant progression at both 1.5 and 2.5 years. Treatment trials would require 62 (1.5 years) or 30 (2.5 years) patients to detect a 70% reduction in the progression of the LGMDD1 questionnaire. INTERPRETATION This study is the largest description of LGMDD1 patients to date and highlights potential genotype-dependent differences that need to be verified prospectively. Future clinical trials will need to account for variability in these key phenotypic features when selecting outcome measures and enrolling patients.
Collapse
Affiliation(s)
- Andrew R. Findlay
- Neuromuscular Division, Department of NeurologyWashington University Saint LouisSaint LouisMissouriUSA
| | - Sarah E. Robinson
- Neuromuscular Division, Department of NeurologyWashington University Saint LouisSaint LouisMissouriUSA
| | - Stephanie Poelker
- Neuromuscular Division, Department of NeurologyWashington University Saint LouisSaint LouisMissouriUSA
| | - Michelle Seiffert
- Neuromuscular Division, Department of NeurologyWashington University Saint LouisSaint LouisMissouriUSA
| | - Rocio Bengoechea
- Neuromuscular Division, Department of NeurologyWashington University Saint LouisSaint LouisMissouriUSA
| | - Conrad C. Weihl
- Neuromuscular Division, Department of NeurologyWashington University Saint LouisSaint LouisMissouriUSA
| |
Collapse
|
5
|
Allosteric Modulation of GSK-3β as a New Therapeutic Approach in Limb Girdle Muscular Dystrophy R1 Calpain 3-Related. Int J Mol Sci 2021; 22:ijms22147367. [PMID: 34298987 PMCID: PMC8308041 DOI: 10.3390/ijms22147367] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2021] [Revised: 06/28/2021] [Accepted: 07/06/2021] [Indexed: 12/28/2022] Open
Abstract
Limb-girdle muscular dystrophy R1 calpain 3-related (LGMDR1) is an autosomal recessive muscular dystrophy produced by mutations in the CAPN3 gene. It is a rare disease and there is no cure or treatment for the disease while the pathophysiological mechanism by which the absence of calpain 3 provokes the dystrophy in muscles is not clear. However, key proteins implicated in Wnt and mTOR signaling pathways, which regulate muscle homeostasis, showed a considerable reduction in their expression and in their phosphorylation in LGMDR1 patients' muscles. Finally, the administration of tideglusib and VP0.7, ATP non-competitive inhibitors of glycogen synthase kinase 3β (GSK-3β), restore the expression and phosphorylation of these proteins in LGMDR1 cells, opening the possibility of their use as therapeutic options.
Collapse
|
6
|
Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia. Cells 2021; 10:cells10051017. [PMID: 33925786 PMCID: PMC8146089 DOI: 10.3390/cells10051017] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2021] [Revised: 04/22/2021] [Accepted: 04/23/2021] [Indexed: 12/19/2022] Open
Abstract
Inflammation-mediated skeletal muscle wasting occurs in patients with sepsis and cancer cachexia. Both conditions severely affect patient morbidity and mortality. Lithium chloride has previously been shown to enhance myogenesis and prevent certain forms of muscular dystrophy. However, to our knowledge, the effect of lithium chloride treatment on sepsis-induced muscle atrophy and cancer cachexia has not yet been investigated. In this study, we aimed to examine the effects of lithium chloride using in vitro and in vivo models of cancer cachexia and sepsis. Lithium chloride prevented wasting in myotubes cultured with cancer cell-conditioned media, maintained the expression of the muscle fiber contractile protein, myosin heavy chain 2, and inhibited the upregulation of the E3 ubiquitin ligase, Atrogin-1. In addition, it inhibited the upregulation of inflammation-associated cytokines in macrophages treated with lipopolysaccharide. In the animal model of sepsis, lithium chloride treatment improved body weight, increased muscle mass, preserved the survival of larger fibers, and decreased the expression of muscle-wasting effector genes. In a model of cancer cachexia, lithium chloride increased muscle mass, enhanced muscle strength, and increased fiber cross-sectional area, with no significant effect on tumor mass. These results indicate that lithium chloride exerts therapeutic effects on inflammation-mediated skeletal muscle wasting, such as sepsis-induced muscle atrophy and cancer cachexia.
Collapse
|
7
|
Qian FY, Guo YD, Zu J, Zhang JH, Zheng YM, Abdoulaye IA, Pan ZH, Xie CM, Gao HC, Zhang ZJ. A novel recessive mutation affecting DNAJB6a causes myofibrillar myopathy. Acta Neuropathol Commun 2021; 9:23. [PMID: 33557929 PMCID: PMC7869515 DOI: 10.1186/s40478-020-01046-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Accepted: 10/02/2020] [Indexed: 11/10/2022] Open
Abstract
Mutations in the DNAJB6 gene have been identified as rare causes of myofibrillar myopathies. However, the underlying pathophysiologica mechanisms remain elusive. DNAJB6 has two known isoforms, including the nuclear isoform DNAJB6a and the cytoplasmic isoform DNAJB6b, which was thought to be the pathogenic isoform. Here, we report a novel recessive mutation c.695_699del (p. Val 232 Gly fs*7) in the DNAJB6 gene, associated with an apparently recessively inherited late onset distal myofibrillar myopathy in a Chinese family. Notably, the novel mutation localizes to exon 9 and uniquely encodes DNAJB6a. We further identified that this mutation decreases the mRNA and protein levels of DNAJB6a and results in an age-dependent recessive toxic effect on skeletal muscle in knock-in mice. Moreover, the mutant DNAJB6a showed a dose-dependent anti-aggregation effect on polyglutamine-containing proteins in vitro. Taking together, these findings reveal the pathogenic role of DNAJB6a insufficiency in myofibrillar myopathies and expand upon the molecular spectrum of DNAJB6 mutations.
Collapse
|
8
|
Bengoechea R, Findlay AR, Bhadra AK, Shao H, Stein KC, Pittman SK, Daw JA, Gestwicki JE, True HL, Weihl CC. Inhibition of DNAJ-HSP70 interaction improves strength in muscular dystrophy. J Clin Invest 2020; 130:4470-4485. [PMID: 32427588 PMCID: PMC7410071 DOI: 10.1172/jci136167] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2020] [Accepted: 05/14/2020] [Indexed: 12/12/2022] Open
Abstract
Dominant mutations in the HSP70 cochaperone DNAJB6 cause a late-onset muscle disease termed limb-girdle muscular dystrophy type D1 (LGMDD1), which is characterized by protein aggregation and vacuolar myopathology. Disease mutations reside within the G/F domain of DNAJB6, but the molecular mechanisms underlying dysfunction are not well understood. Using yeast, cell culture, and mouse models of LGMDD1, we found that the toxicity associated with disease-associated DNAJB6 required its interaction with HSP70 and that abrogating this interaction genetically or with small molecules was protective. In skeletal muscle, DNAJB6 localizes to the Z-disc with HSP70. Whereas HSP70 normally diffused rapidly between the Z-disc and sarcoplasm, the rate of diffusion of HSP70 in LGMDD1 mouse muscle was diminished, probably because it had an unusual affinity for the Z-disc and mutant DNAJB6. Treating LGMDD1 mice with a small-molecule inhibitor of the DNAJ-HSP70 complex remobilized HSP70, improved strength, and corrected myopathology. These data support a model in which LGMDD1 mutations in DNAJB6 are a gain-of-function disease that is, counterintuitively, mediated via HSP70 binding. Thus, therapeutic approaches targeting HSP70-DNAJB6 may be effective in treating this inherited muscular dystrophy.
Collapse
Affiliation(s)
| | | | - Ankan K. Bhadra
- Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA
| | - Hao Shao
- Institute for Neurodegenerative Diseases, UCSF, San Francisco, California, USA
| | - Kevin C. Stein
- Department of Biology, Stanford University, Stanford, California, USA
| | | | | | - Jason E. Gestwicki
- Institute for Neurodegenerative Diseases, UCSF, San Francisco, California, USA
| | - Heather L. True
- Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA
| | | |
Collapse
|
9
|
Whitley KC, Hamstra SI, Baranowski RW, Watson CJF, MacPherson REK, MacNeil AJ, Roy BD, Vandenboom R, Fajardo VA. GSK3 inhibition with low dose lithium supplementation augments murine muscle fatigue resistance and specific force production. Physiol Rep 2020; 8:e14517. [PMID: 32729236 PMCID: PMC7390913 DOI: 10.14814/phy2.14517] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Revised: 06/30/2020] [Accepted: 07/02/2020] [Indexed: 12/20/2022] Open
Abstract
Calcineurin is a Ca2+ -dependent serine/threonine phosphatase that dephosphorylates nuclear factor of activated T cells (NFAT), allowing for NFAT entry into the nucleus. In skeletal muscle, calcineurin signaling and NFAT activation increases the expression of proliferator-activated receptor-gamma coactivator 1-alpha (PGC-1α) and slow myosin heavy chain (MHC) I ultimately promoting fatigue resistance. Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that antagonizes calcineurin by re-phosphorylating NFAT preventing its entry into the nucleus. Here, we tested whether GSK3 inhibition in vivo with low dose lithium chloride (LiCl) supplementation (10 mg kg-1 day-1 for 6 weeks) in male C57BL/6J mice would enhance muscle fatigue resistance in soleus and extensor digitorum longus (EDL) muscles by activating NFAT and augmenting PGC-1α and MHC I expression. LiCl treatment inhibited GSK3 by elevating Ser9 phosphorylation in soleus (+1.8-fold, p = .007) and EDL (+1.3-fold p = .04) muscles. This was associated with a significant reduction in NFAT phosphorylation (-50%, p = .04) and a significant increase in PGC-1α (+1.5-fold, p = .05) in the soleus but not the EDL. MHC isoform analyses in the soleus also revealed a 1.2-fold increase in MHC I (p = .04) with no change in MHC IIa. In turn, a significant enhancement in soleus muscle fatigue (p = .04), but not EDL (p = .26) was found with LiCl supplementation. Lastly, LiCl enhanced specific force production in both soleus (p < .0001) and EDL (p = .002) muscles. Altogether, our findings show the skleletal muscle contractile benefits of LiCl-mediated GSK3 inhibition in mice.
Collapse
Affiliation(s)
- Kennedy C. Whitley
- Department of KinesiologyBrock UniversitySt. CatharinesONCanada
- Centre for Bone and Muscle HealthBrock UniversitySt. CatharinesONCanada
| | - Sophie I. Hamstra
- Department of KinesiologyBrock UniversitySt. CatharinesONCanada
- Centre for Bone and Muscle HealthBrock UniversitySt. CatharinesONCanada
| | - Ryan W. Baranowski
- Department of KinesiologyBrock UniversitySt. CatharinesONCanada
- Centre for Bone and Muscle HealthBrock UniversitySt. CatharinesONCanada
| | | | | | - Adam J. MacNeil
- Department of Health SciencesBrock UniversitySt. CatharinesONCanada
| | - Brian D. Roy
- Department of KinesiologyBrock UniversitySt. CatharinesONCanada
- Centre for Bone and Muscle HealthBrock UniversitySt. CatharinesONCanada
| | - Rene Vandenboom
- Department of KinesiologyBrock UniversitySt. CatharinesONCanada
- Centre for Bone and Muscle HealthBrock UniversitySt. CatharinesONCanada
| | - Val A. Fajardo
- Department of KinesiologyBrock UniversitySt. CatharinesONCanada
- Centre for Bone and Muscle HealthBrock UniversitySt. CatharinesONCanada
| |
Collapse
|
10
|
Neuromuscular Diseases Due to Chaperone Mutations: A Review and Some New Results. Int J Mol Sci 2020; 21:ijms21041409. [PMID: 32093037 PMCID: PMC7073051 DOI: 10.3390/ijms21041409] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Revised: 02/12/2020] [Accepted: 02/13/2020] [Indexed: 12/12/2022] Open
Abstract
Skeletal muscle and the nervous system depend on efficient protein quality control, and they express chaperones and cochaperones at high levels to maintain protein homeostasis. Mutations in many of these proteins cause neuromuscular diseases, myopathies, and hereditary motor and sensorimotor neuropathies. In this review, we cover mutations in DNAJB6, DNAJB2, αB-crystallin (CRYAB, HSPB5), HSPB1, HSPB3, HSPB8, and BAG3, and discuss the molecular mechanisms by which they cause neuromuscular disease. In addition, previously unpublished results are presented, showing downstream effects of BAG3 p.P209L on DNAJB6 turnover and localization.
Collapse
|
11
|
Kurgan N, Whitley KC, Maddalena LA, Moradi F, Stoikos J, Hamstra SI, Rubie EA, Kumar M, Roy BD, Woodgett JR, Stuart JA, Fajardo VA. A Low-Therapeutic Dose of Lithium Inhibits GSK3 and Enhances Myoblast Fusion in C2C12 Cells. Cells 2019; 8:cells8111340. [PMID: 31671858 PMCID: PMC6912290 DOI: 10.3390/cells8111340] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Revised: 10/23/2019] [Accepted: 10/26/2019] [Indexed: 12/14/2022] Open
Abstract
Glycogen synthase kinase 3 (GSK3) slows myogenic differentiation and myoblast fusion partly by inhibiting the Wnt/β-catenin signaling pathway. Lithium, a common medication for bipolar disorder, inhibits GSK3 via Mg+ competition and increased Ser21 (GSK3α) or Ser9 (GSK3β) phosphorylation, leading to enhanced myoblast fusion and myogenic differentiation. However, previous studies demonstrating the effect of lithium on GSK3 have used concentrations up to 10 mM, which greatly exceeds concentrations measured in the serum of patients being treated for bipolar disorder (0.5–1.2 mM). Here, we determined whether a low-therapeutic (0.5 mM) dose of lithium could promote myoblast fusion and myogenic differentiation in C2C12 cells. C2C12 myotubes differentiated for three days in media containing 0.5 mM lithium chloride (LiCl) had significantly higher GSK3β (ser9) and GSK3α (ser21) phosphorylation compared with control myotubes differentiated in the same media without LiCl (+2–2.5 fold, p < 0.05), a result associated with an increase in total β-catenin. To further demonstrate that 0.5 mM LiCl inhibited GSK3 activity, we also developed a novel GSK3-specific activity assay. Using this enzyme-linked spectrophotometric assay, we showed that 0.5 mM LiCl-treated myotubes had significantly reduced GSK3 activity (−86%, p < 0.001). Correspondingly, 0.5 mM LiCl treated myotubes had a higher myoblast fusion index compared with control (p < 0.001) and significantly higher levels of markers of myogenesis (myogenin, +3-fold, p < 0.001) and myogenic differentiation (myosin heavy chain, +10-fold, p < 0.001). These results indicate that a low-therapeutic dose of LiCl is sufficient to promote myoblast fusion and myogenic differentiation in muscle cells, which has implications for the treatment of several myopathic conditions.
Collapse
Affiliation(s)
- Nigel Kurgan
- Department of Kinesiology, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada; (N.K.); (K.C.W.); (J.S.); (S.I.H.); (B.D.R.)
- Centre for Bone and Muscle Health, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada
| | - Kennedy C. Whitley
- Department of Kinesiology, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada; (N.K.); (K.C.W.); (J.S.); (S.I.H.); (B.D.R.)
- Centre for Bone and Muscle Health, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada
| | - Lucas A. Maddalena
- Department of Biological Sciences, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada; (L.A.M.); (F.M.); (J.A.S.)
| | - Fereshteh Moradi
- Department of Biological Sciences, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada; (L.A.M.); (F.M.); (J.A.S.)
| | - Joshua Stoikos
- Department of Kinesiology, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada; (N.K.); (K.C.W.); (J.S.); (S.I.H.); (B.D.R.)
| | - Sophie I. Hamstra
- Department of Kinesiology, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada; (N.K.); (K.C.W.); (J.S.); (S.I.H.); (B.D.R.)
- Centre for Bone and Muscle Health, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada
| | - Elizabeth A. Rubie
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System, 600 University Avenue, Toronto, ON M5G 1X5, Canada; (E.A.R.); (M.K.); (J.R.W.)
| | - Megha Kumar
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System, 600 University Avenue, Toronto, ON M5G 1X5, Canada; (E.A.R.); (M.K.); (J.R.W.)
| | - Brian D. Roy
- Department of Kinesiology, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada; (N.K.); (K.C.W.); (J.S.); (S.I.H.); (B.D.R.)
- Centre for Bone and Muscle Health, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada
| | - James R. Woodgett
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System, 600 University Avenue, Toronto, ON M5G 1X5, Canada; (E.A.R.); (M.K.); (J.R.W.)
| | - Jeffrey A. Stuart
- Department of Biological Sciences, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada; (L.A.M.); (F.M.); (J.A.S.)
| | - Val A. Fajardo
- Department of Kinesiology, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada; (N.K.); (K.C.W.); (J.S.); (S.I.H.); (B.D.R.)
- Centre for Bone and Muscle Health, Brock University 1812 Sir Isaac Brock Way, St. Catharines, ON L2S 3A1, Canada
- Correspondence:
| |
Collapse
|